Michael York
Keine laufenden Positionen mehr
Vermögen: 59 629 $ am 31.05.2023
Profil
Michael York served as President & Chief Executive Officer at Sente, Inc. from 2013 to 2014.
He was Vice President-Specialty & Rare Disease Unit at Amylin Pharmaceuticals, Inc. He also served as Vice President-Global Business Development at Orexigen Therapeutics, Inc. from 2015 to 2018.
From 2018 to 2021, he was Vice President-Development & Commercial Strategy at PhaseBio Pharmaceuticals, Inc. He served as President & Chief Executive Officer at SENTÉ Labs.
In 2021, he became President, CEO, CFO, Secretary & Treasurer at Metacrine, Inc. Mr. York received his undergraduate degree from San Diego State University and his MBA from the University of Redlands.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
METACRINE INC
0,25% | 03.02.2023 | 107 054 ( 0,25% ) | 59 629 $ | 31.05.2023 |
Ehemalige bekannte Positionen von Michael York
| Unternehmen | Position | Ende |
|---|---|---|
| METACRINE, INC. | Chief Executive Officer | 24.03.2023 |
| PHASEBIO PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.11.2021 |
| OREXIGEN THERAPEUTICS, INC. | Corporate Officer/Principal | 01.06.2018 |
| Sente, Inc. | Chief Executive Officer | 01.12.2014 |
| SENTÉ Labs | Chief Executive Officer | - |
Ausbildung von Michael York
| San Diego State University | Undergraduate Degree |
| University of Redlands | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| PHASEBIO PHARMACEUTICALS, INC. | Health Technology |
| METACRINE, INC. | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Amylin Pharmaceuticals, Inc.
 Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Health Technology |
Orexigen Therapeutics, Inc.
 Orexigen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Orexigen Therapeutics, Inc. is a biopharmaceutical company, which focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its primary activities include recruiting personnel, conducting research and development, including clinical trials, raising capital, and preparing for the marketing and commercialization of its product, contrave. The company was founded by Eckard Weber in September 2002 and is headquartered in La Jolla, CA. | Health Technology |
| Sente, Inc. | Technology Services |
| SENTÉ Labs |
